Company: MLSS
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001493152-25-022276
Chunk: 93

Company: MILESTONE SCIENTIFIC INC.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 8
Chunk 93
---
 to evaluate financing opportunities to support working capital
requirements, product commercialization, and potential future growth initiatives.

Consideration of Company’s ability to continue as a going
concern

The accompanying financial statements have been prepared in conformity
with U.S. generally accepted accounting principles (GAAP), which contemplate the continuation of the Company as a going concern. The going
concern basis assumes that assets will be realized and liabilities will be settled in the ordinary course of business at the amounts disclosed
in the unaudited condensed financial statements.

Since its inception, the Company has incurred
aggregate losses of approximately $132.7 million. Operating losses were approximately $1.1 million and $4.6 million for the three
and nine months ended September 30, 2025, respectively. As of September 30, 2025, Milestone Scientific had cash and cash equivalents
of approximately $1.3 million and working capital of approximately $3.1 million. Net cash flows used in operating activities were
approximately $2.7 million and $1.4 million for the nine months ended September 30, 2025, and 2024, respectively. Based on the
Company’s available cash resources, recurring operating losses, accumulated deficit, and the need for additional capital to
finance ongoing operations. Management has concluded that substantial doubt exists about the Company’s ability to continue as a
going concern for a period of one year from the date these unaudited condensed financial statements are issued.

Management is actively pursuing additional sources of funding through equity
and debt financing to support the Company’s operating plan. Although Milestone Scientific has successfully raised capital in the
past, there can be no assurance that additional financing will be available on acceptable terms, or at all. The terms of any such financing
may adversely affect the rights or holdings of existing stockholders.

The Company continues to focus on generating positive cash flow from operations
by increasing revenue from its dental business worldwide, expanding sales of its medical devices and disposables in the United States
and abroad, and reducing operating expenses. However, the continuation of operations is dependent upon the Company’s ability to
raise additional capital and ultimately achieve sustained profitability.

 25 

Item
3. Quantitative and Qualitative Disclosures about Market Risk

Milestone
Scientific is a “smaller reporting company” as defined by Regulation S-K and, as such, is not required to provide the information
required by this item.

Item
4. Controls and Procedures

Evaluation of Disclosure